



1/2 2613

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)			Docket No. PU5025USW	
Applicant(s): Goodson et al.				
Application No. 10/533,325	Filing Date May 2, 2005	Examiner	Customer No. 23347	Group Art Unit 2613
Invention: Pharmaceutical Antiviral Compositions				
<div></div> <p>I hereby certify that this <u>Supplemental IDS w/references</u> (Identify type of correspondence)</p> <p>is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on <u>November 17, 2005</u> (Date)</p> <p><u>Valerie L. Phillips</u> (Typed or Printed Name of Person Mailing Correspondence)</p> <p><u>Valerie L. Phillips</u> (Signature of Person Mailing Correspondence)</p> <div></div>				



PU5025USW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Goodson et al.

Serial No.: 10/533,325

Group Art Unit: 2613

File Date: May 2, 2005

Examiner:

For: Phamaceutical Antiviral Compositions

Director of the U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ Copies of the references are enclosed: Ref. 7-12
☐ Copies of the references were submitted in parent application _____ (37 CFR 1.98(d))
☐ A copy of the International Search Report which issued on International Application No. PCT/US03/035830 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

- A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

- ☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action or after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

- B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:

- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311, whichever occurs first.

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.


In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,


Karen L. Prus
Registration No. 39,337

Date: *November 16, 2005*
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-2192
Facsimile: (919) 483-7988

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1	4,724,232	Feb. 9, 1988	Rideout et al.			
	2	5,047,407	Sept. 10, 1991	Belleau et al.			
	3	5,859,021	Jan. 12, 1999	Cameron et al.			
	4	5,905,082	May 18, 1999	Roberts et al.			
	5	6,113,920	Sept. 5, 2000	Maye et al.			
	6	6,180,639	Jan. 30, 2001	Coates et al.			

FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	7	EP 0382526	Aug. 16, 1990	EUROPE			
	8	WO 91/17159	Nov. 14, 1991	WIPO			
	9	WO 92/20344	Nov. 26, 1992	WIPO			
	10	WO 92/20669	Nov. 26, 1992	WIPO			
	11	WO 92/21676	Dec. 10, 1992	WIPO			
	12	WO 95/29174	Nov. 2, 1995	WIPO			

[illegible]

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.